Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 566 matching trials from the live ClinicalTrials.gov search.
Conditions
Uterine Cervical Neoplasms, Ovarian Neoplasms, Gynecologic Neoplasms, Fallopian Tube Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Peritoneal Neoplasms
Interventions
Specialized Symptom Management and Supportive Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pelvic Organ Prolapse, Uterovaginal Prolapse, Vaginal Vault Prolapse, Cystocele
Interventions
Absorbable Suture and Permanent Suture
Other
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Vaginosis, Bacterial, Vaginal Infection
Interventions
GW05, Metronidazole
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
20
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • San Diego, California + 16 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
HIV Infections
Interventions
BufferGel, PRO 2000/5 Gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Bacterial Vaginosis, Vaginal Microbiome, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginitis
Interventions
Menstrual Cup
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
15 Years to 35 Years · Female only
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Papanicolaou Smear
Interventions
no-stirrup vaginal examination, Vaginal speculum examination done with stirrups.
Procedure
Lead sponsor
Eisenhower Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Fort Gordon, Georgia
Conditions
Pregnancy Trimester, First, Abortion, Threatened
Interventions
Thromboelastometry testing
Diagnostic Test
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infections
Interventions
Tenofovir 1% vaginal gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Polycystic Ovary Syndrome
Interventions
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
Drug · Diagnostic Test · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Conditions
Cervical Cancer, Sexuality and Reproductive Issues
Interventions
management of therapy complications
Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Up to 69 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Savannah, Georgia • Kalamazoo, Michigan • Kalamazooaa, Michigan + 8 more
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA Gel

NCT00028132
Conditions
HIV Infections
Interventions
Tenofovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
5
States / cities
New York, New York • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Outcomes Following Vaginal Prolapse Repair and Mid Urethral Sling Trial

NCT00460434
Conditions
Pelvic Organ Prolapse
Interventions
TVT, Sham
Device · Other
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
18 Years and older · Female only
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 5 more
Conditions
Vulvar Dysplasia, Vaginal Dysplasia
Interventions
CO2 laser surgery, ultrasonic surgical aspiration
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Cervical Cancer, Vaginal Cancer
Interventions
paclitaxel
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2004
U.S. locations
50
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 40 more
Conditions
Atrophic Vaginitis
Interventions
Estriol, Estradiol valerate, Vanicream Lite
Drug
Lead sponsor
Maire Mac Bride
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Sacral Colpopexy, Pelvic Organ Prolapse
Interventions
Not listed
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morristown, New Jersey
Conditions
Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions
Pixel CO2 Laser System
Procedure
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Weston, Florida
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions
Replens and coconut oil
Combination Product
Lead sponsor
Alta Bates Summit Medical Center
Other
Eligibility
Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Berkeley, California
Conditions
Candidiasis, Vulvovaginal
Interventions
OCF001 Intravaginal Gel, Placebo Gel
Drug
Lead sponsor
Sano Chemicals Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Bacterial Vaginosis
Interventions
0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel, Placebo Gel
Drug · Other
Lead sponsor
Starpharma Pty Ltd
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Phoenix, Arizona • Denver, Colorado • Las Vegas, Nevada + 2 more
Conditions
Urinary Incontinence, Stress, Uterine Prolapse, Vaginal Prolapse
Interventions
Burch urethropexy at time of sacrocolpopexy
Procedure
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Birmingham, Alabama • Maywood, Illinois • Iowa City, Iowa + 4 more
Conditions
Menopause, Genitourinary Syndrome of Menopause, Vulvovaginal Atrophy, Menopause Syndrome, Dyspareunia
Interventions
Intrarosa, Placebos
Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
40 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • New York, New York